This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1569 entries already.
Belgian biopharma UCB has agreed to acquire clinical-stage biotech Neurona Therapeutics for up to US$1.15 billion, betting on a one-off cell therapy that aims to structurally repair the brains of people with drug-resistant epilepsy.
A newly launched Finnish deep-tech company has cracked the code for single-molecule protein detection. VTT-originated Proteins.1 has launched with €4.7m in pre-seed funding, aiming to stop the deadliest diseases before symptoms even appear.
Spain has launched a US$200m venture capital fund anchored in Boston to help Spanish biotech companies scale in one of the world’s foremost life sciences ecosystem. The initiative includes a new trade office in Massachusetts and around US$57m in public seed capital.
Novo Nordisk becomes the latest major pharma player to trust the future of its drug discovery to AI. However, the Danish pharma heavyweight is going one step further: The partnership with Open AI is set to embed advanced artificial intelligence across everything from early R&D to commercial operations.
The recent resurgence of life sciences IPOs in the US highlights a persistent structural imbalance: Europe generates world-class science but struggles to finance and retain it. The European Life Sciences Coalition was created to address this gap by mobilizing institutional capital and strengthening the policy framework needed to scale European innovation at home.
For decades, biotech companies were formed around a discovery: a promising biological signal, a novel target, a platform emerging from academic research. Now a different formation model is gaining momentum: venture studios. These entities don’t just fund startups, they assemble them, testing hypotheses, building teams and infrastructure, and only then spinning out companies designed to scale.
Copenhagen-based biotech Adcendo ApS has closed an oversubscribed US$75 million Series C round led by Jeito Capital. The funds will fuel early-phase trials of three ADC candidates for cancers with high unmet need.
Clean Food Group has secured £4.5 million from a group of investors led by Clean Growth Fund and New Agrarian, together with £700,000 in non-dilutive funding from Innovate UK. The London-based biotech will use the funds to accelerate the ramp-up of the world’s largest yeast-based oils and fats facility in Knowsley, Liverpool.
Mainz‑based biotech BioNTech has presented compelling Phase II data for its compound trastuzumab pamirtecan. The antibody–drug conjugate (ADC) was evaluated in patients with advanced uterine cancer who had previously undergone multiple lines of treatment.
Amid chronic under-investments in new antibacterial weapons, Basilea Pharmaceutica has secured an additional US$6 million from CARB‑X to fund the first‑in‑human Phase I trial of a novel Gram‑negative antibiotic now entering early clinical development. The compound BAL2420 targets LptA, part of the lipopolysaccharide transport bridge that Gram negative bacteria rely on to build their outer membrane.